Sweet adhesins: Probing bacterial glycoproteins with novel tools to inspire future antibacterial strategies
The STICKY SUGARS project aims to develop methods for visualizing and quantifying bacterial adhesin sugars to establish them as novel antibacterial targets against resistant infections.
Projectdetails
Introduction
With bacteria increasingly resistant to current antibiotics, new strategies to fight infection are needed. Bacterial adhesin proteins, which play an important role in the establishment of infection, appear to be promising targets for novel therapies. Adhesins enable the first contact between bacteria and host cells.
Importance of Adhesins
We know that some adhesins are modified with highly unique sugars that are important for adhesin stability and adherence. However, we do not know how widespread this modification is, and whether it constitutes a good target for antibacterial strategies.
Challenges in Research
A lack of suitable methods for the detection of bacterial adhesin sugars has impeded the detailed study of these sugars, blocking further efforts to develop antibacterial strategies against bacterial adhesin sugars.
Project Goals
In this project, I aim to revolutionize our understanding of adhesin sugars, in terms of timing and prevalence of the modification, which is crucial information to start targeting adhesin sugars.
Innovative Approach
To this end, I have designed an innovative approach that combines the strengths of:
- Carbohydrate chemistry
- Enzymology
- Microbiology
- Molecular dynamics
This approach will enable us to:
- Establish straightforward methods to selectively visualize and quantify the adhesin sugars directly on the surface of bacterial cells.
- Detect the presence of adhesin sugars under changing growth conditions and in relevant clinical isolates.
- Develop a computational method to predict the presence of sugars on adhesins that have not yet been identified.
Recent Findings
Recent findings from my team on the process of adhesin modification underscore the uniqueness of adhesin sugars, and this experience puts me in an ideal position to start this project.
Overall Goal
The overarching goal of STICKY SUGARS is to lay the foundation for the exploitation of adhesin sugars as antibacterial targets. By visualizing adhesin sugars directly on bacteria, we can observe their response to antibacterial treatments and pave the way toward clinical applications in the future.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.499.251 |
Totale projectbegroting | € 1.499.251 |
Tijdlijn
Startdatum | 1-5-2023 |
Einddatum | 30-4-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- RIJKSUNIVERSITEIT GRONINGENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
All-in-one supramolecular approach as an innovative anti-infectious strategyPATHO-LEGO aims to develop hybrid molecules that simultaneously block Pseudomonas aeruginosa adhesion and recruit natural antibodies to enhance immune clearance of resistant strains. | ERC Proof of... | € 150.000 | 2023 | Details |
Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolutionGlyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment. | ERC Starting... | € 1.500.000 | 2023 | Details |
Glycan Mimetics for Cell Glycocalyx Reconstitution: a polymer chemist’s approach to fight infectionGLYMCE aims to uncover how carbohydrates influence pathogen interactions to create innovative glycopolymer materials for infection prevention and treatment. | ERC Consolid... | € 1.994.024 | 2024 | Details |
Breaking down barriers against antimicrobials: elucidating a cross-kingdom novel lipid transport mechanismThis project aims to characterize DedA proteins to uncover their role in lipid transport and cell envelope biogenesis in Gram-negative bacteria, addressing antimicrobial resistance mechanisms. | ERC Starting... | € 1.472.710 | 2025 | Details |
ADPribosylation and Ubiquitination; post-translational interplayThis project aims to investigate the interplay between ubiquitination and ADPribosylation in cellular processes to develop novel therapeutic strategies for diseases like infections and cancer. | ERC Consolid... | € 1.999.625 | 2024 | Details |
All-in-one supramolecular approach as an innovative anti-infectious strategy
PATHO-LEGO aims to develop hybrid molecules that simultaneously block Pseudomonas aeruginosa adhesion and recruit natural antibodies to enhance immune clearance of resistant strains.
Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolution
Glyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment.
Glycan Mimetics for Cell Glycocalyx Reconstitution: a polymer chemist’s approach to fight infection
GLYMCE aims to uncover how carbohydrates influence pathogen interactions to create innovative glycopolymer materials for infection prevention and treatment.
Breaking down barriers against antimicrobials: elucidating a cross-kingdom novel lipid transport mechanism
This project aims to characterize DedA proteins to uncover their role in lipid transport and cell envelope biogenesis in Gram-negative bacteria, addressing antimicrobial resistance mechanisms.
ADPribosylation and Ubiquitination; post-translational interplay
This project aims to investigate the interplay between ubiquitination and ADPribosylation in cellular processes to develop novel therapeutic strategies for diseases like infections and cancer.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Inhibitor-Mediated Programming of GlycoformsThe project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions. | EIC Pathfinder | € 2.998.878 | 2025 | Details |
Precision control of glycosylation to open a new era of therapeutic antibodiesGlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments. | EIC Transition | € 2.499.540 | 2025 | Details |
Inhibitor-Mediated Programming of Glycoforms
The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.
Precision control of glycosylation to open a new era of therapeutic antibodies
GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.